RE:RE:TLTSo far then, Hematology, blood chemistry and urinalysis for safety purposes have been carried out on patients 1, 2, and 3. for days 1, and 3.
For patient 1, also day 30 has been carried out. With patient 2, another 7 days and patient 3, another 13 days for those two to reach the 30 day mark.
After Primary and Secondary end points have been reached much will depend on the Independent Data and Safety Monitoring Board (DSMB) review. Assuming that the DSMB report is a positive one as I'm sure all, except maybe bionicjoe, hope and expect, there can still be variations in the wording of the report that can affect TLT's price in the near term. For instance, despite a positive report and recommendation there could be some mention of inflammation or some small but easily overcome glitches.
On the other hand there could be an absolutely glowing report full of positives, for instance a report of significant tumor reduction, and this with only half of the recommended eventual dose.
Either of these two scenarios could affect the stock price. The first one positively, the second one extremely positively.
All of this, JMO. and shows how little I understand the science and how much I rely on many of the posters for my education.